Oral miltefosine for Indian visceral leishmaniasis

New England Journal of Medicine

Volumn 347, Issue 22, 2002, Pages 1739-1746

  Sundar, Shyam ^a   Jha, T K ^b   Thakur, C P ^c   Engel, Juergen ^d   Sindermann, Herbert ^d   Fischer, Christina ^d   Junge, Klaus ^d   Bryceson, Anthony ^e   Berman, Jonathan ^f,g  

^a BANARAS HINDU UNIVERSITY   (India)

^b Kala azar Research Center   (India)

^c Balaji Utthan Sansthan   (India)

^d ASTA MEDICA AG   (Germany)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g Natl Ctr for Complementary Med   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; METRONIDAZOLE; MILTEFOSINE; NITROGEN; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL MENINGITIS; BLEEDING; BLISTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG HYPERSENSITIVITY; EPISTAXIS; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HEMORRHOID; HUMAN; HYPERBILIRUBINEMIA; INDIA; MAJOR CLINICAL STUDY; MALARIA; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RIGOR; SIDE EFFECT; SKIN ABRASION; SKIN NECROSIS; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; INDIA; INFUSIONS, INTRAVENOUS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; RECURRENCE; SPLEEN;

EID: 0037191710     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021556     Document Type: Article

References (20)

1. Desjeux P. Leishmaniasis: Public health aspects and control. Clin Dermatol 1996;14:417-23.
2. Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
3. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
4. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: A randomized comparison. Bull World Health Organ 1994;72:931-6.
5. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial. BMJ 2001;323:419-22.
6. Lux H, Heise N, Klenner T, Hart D, Opperdoes FD. Ether-lipid (alkylphospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 2000;111:1-14.
7. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6.
8. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: Oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:1630-4.
9. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
10. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999;93:589-97.
11. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800.
12. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000;31:1110-3.
13. Cancer Therapy Evaluation Program. Common Toxicity Criteria. Rockville, Md.: National Cancer Institute, 2002. (Accessed October 7, 2002, at http://ctep.cancer.gov/reporting/index.html.)
14. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
15. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypotheses of non-zero risk difference or non-unity relative risk. Stat Med 1990;9:1447-54.
16. Center for Drug Evaluation and Research. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. Rockville, Md.: Food and Drug Administration, April 1996. (Accessed October 7, 2002, at http://www.fda.gov/cder/guidance/959fnl.pdf.)
17. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001;6:928-34.
18. Jha SN, Singh NKP, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991;39:314-6.
19. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: A randomized study. Am J Trop Med Hyg 1991;45:435-41.
20. Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5.